Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal | Reuters

ReutersView source article

Part of story

FDA rejects Summit Therapeutics and Akeso's ivonescimab for lung cancer

The FDA declined to approve ivonescimab, a bispecific antibody from Summit Therapeutics and Akeso, after the trial missed its key overall survival endpoint in a narrow lung cancer setting. Analysts had largely anticipated the rejection.

Nov 15, 2026·2 sourcesCancer and Cancer TreatmentClinical trialsCancer treatmentCancer & OncologyDrug Policy, Pricing & ApprovalFDA drug approvalClinical trial endpoints
FDA rejects Summit Therapeutics and Akeso's ivonescimab for lung cancer
00

Other sources for this story

Endpoints

FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting